Cargando…

Economic Value of Dengue Vaccine in Thailand

With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Bruce Y., Connor, Diana L., Kitchen, Sarah B., Bacon, Kristina M., Shah, Mirat, Brown, Shawn T., Bailey, Rachel R., Laosiritaworn, Yongjua, Burke, Donald S., Cummings, Derek A. T.
Formato: Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083745/
https://www.ncbi.nlm.nih.gov/pubmed/21540387
http://dx.doi.org/10.4269/ajtmh.2011.10-0624
_version_ 1782202447542878208
author Lee, Bruce Y.
Connor, Diana L.
Kitchen, Sarah B.
Bacon, Kristina M.
Shah, Mirat
Brown, Shawn T.
Bailey, Rachel R.
Laosiritaworn, Yongjua
Burke, Donald S.
Cummings, Derek A. T.
author_facet Lee, Bruce Y.
Connor, Diana L.
Kitchen, Sarah B.
Bacon, Kristina M.
Shah, Mirat
Brown, Shawn T.
Bailey, Rachel R.
Laosiritaworn, Yongjua
Burke, Donald S.
Cummings, Derek A. T.
author_sort Lee, Bruce Y.
collection PubMed
description With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.
format Text
id pubmed-3083745
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-30837452011-05-17 Economic Value of Dengue Vaccine in Thailand Lee, Bruce Y. Connor, Diana L. Kitchen, Sarah B. Bacon, Kristina M. Shah, Mirat Brown, Shawn T. Bailey, Rachel R. Laosiritaworn, Yongjua Burke, Donald S. Cummings, Derek A. T. Am J Trop Med Hyg Articles With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving. The American Society of Tropical Medicine and Hygiene 2011-05-05 /pmc/articles/PMC3083745/ /pubmed/21540387 http://dx.doi.org/10.4269/ajtmh.2011.10-0624 Text en ©The American Society of Tropical Medicine and Hygiene http://creativecommons.org/licenses/by/2.5/ This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Lee, Bruce Y.
Connor, Diana L.
Kitchen, Sarah B.
Bacon, Kristina M.
Shah, Mirat
Brown, Shawn T.
Bailey, Rachel R.
Laosiritaworn, Yongjua
Burke, Donald S.
Cummings, Derek A. T.
Economic Value of Dengue Vaccine in Thailand
title Economic Value of Dengue Vaccine in Thailand
title_full Economic Value of Dengue Vaccine in Thailand
title_fullStr Economic Value of Dengue Vaccine in Thailand
title_full_unstemmed Economic Value of Dengue Vaccine in Thailand
title_short Economic Value of Dengue Vaccine in Thailand
title_sort economic value of dengue vaccine in thailand
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083745/
https://www.ncbi.nlm.nih.gov/pubmed/21540387
http://dx.doi.org/10.4269/ajtmh.2011.10-0624
work_keys_str_mv AT leebrucey economicvalueofdenguevaccineinthailand
AT connordianal economicvalueofdenguevaccineinthailand
AT kitchensarahb economicvalueofdenguevaccineinthailand
AT baconkristinam economicvalueofdenguevaccineinthailand
AT shahmirat economicvalueofdenguevaccineinthailand
AT brownshawnt economicvalueofdenguevaccineinthailand
AT baileyrachelr economicvalueofdenguevaccineinthailand
AT laosiritawornyongjua economicvalueofdenguevaccineinthailand
AT burkedonalds economicvalueofdenguevaccineinthailand
AT cummingsderekat economicvalueofdenguevaccineinthailand